The “RNAi Therapeutics Market (2nd Edition), 2019 - 2030
To order this 350+ page report, which features 130+ figuresand 190+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Inclusions
§ A detailed review of the overalllandscape of companies developing RNAi therapeutics, including information onphase of development (marketed, clinical, and preclinical / discovery stage) ofpipeline candidates, target disease indication(s), key therapeutic areas(oncological disorders, infectious diseases, genetic disorders, ophthalmicdiseases, respiratory disorders, hepatic disorders, metabolic disorders,cardiovascular disorders, dermatological disorders, and others), type of RNAi molecule (siRNA, miRNA, shRNA,sshRNA and DNA), target genes, type of delivery system used, route ofadministration and special drug designations (if any).
§ A competitiveness analysis ofkey players engaged in this domain, evaluating their respective productportfolios, type of RNAi molecule, target therapeutic areas, company size andyear of establishment.
§ An analysis of completed,ongoing and planned clinical studies for different types of RNAi molecules. Thetrials were analyzed on the basis of various relevant parameters, such asregistration year, current status, phase of development, type of RNAi molecule,regional distribution of clinical trials and enrolled patient population.
§ An in-depth analysis of thevarious patents that have been filed / granted related to RNAi therapeutics,since 2014. The analysis also highlights the key parameters associated with thepatents, including information on patent type (granted patents, patent applicationsand others), publication year, regional applicability, CPC symbols, emergingfocus areas, leading industry / non-industry players (in terms of the number ofpatents filed / granted), and patent valuation.
§ An analysis of the variouspartnerships pertaining to RNAi therapeutics, which have been established tillAugust 2019, based on various parameters, such as the type of partnership, yearof partnership, target disease indications, therapeutic area, type of RNAimolecule, financial details (wherever applicable), focus area of collaborationand most active players.
§ An analysis of the investmentsmade at various stages of development in companies engaged in this domain,between 2014-2019, including seed financing, venture capital financing, IPOs,secondary offerings, debt financing, grants and other offerings.
§ An analysis of the keypromotional strategies that have been adopted by developers of marketedoligonucleotide therapeutics, namely Defitelio®, Exondys® and Onpattro®.
§ A review of emerging technologyplatforms and delivery systems that are being used for targeted therapeuticdelivery, featuring detailed profiles of technologies.
§ Detailed profiles of drugcandidates that are in the advanced stages of development (phase II/III andabove), including information on their current development status, mechanism ofaction, route of administration, affiliated delivery technology, dosage, recentclinical trial results along with information on their respective developers.
§ An elaborate discussion on theuse of miRNA as a potential biomarker, along with a list of diagnostic kitsthat are either available in the market, or likely to be approved in theforeseen future.
The USD 9.2 billion (by 2030) financial opportunitywithin the RNAi therapeutics market has been analyzed across the followingsegments:
§ Key therapeutic areas
§ Oncological disorders
§ Infectious diseases
§ Genetic disorders
§ Ophthalmic disorders
§ Hepatic disorders
§ Respiratory disorders
§ Type of RNAi molecule
§ siRNA
§ miRNA
§ shRNA
§ sshRNA
§ DNA
§ Route ofadministration
§ Subcutaneous
§ Intravenous
§ Intradermal
§ Intratumoral
§ Intravitreal
§ Oral
§ Intramuscular
§ Key geographicalregions
§ North America
§ Europe
§ Asia Pacific and the Restof the World
§ Leading Players
Thereport features inputs from eminent industry stakeholder(s), according to whomRNAi therapeutics are promising domain of pharmaceutical industry. The reportincludes detailed transcripts of discussions held with the following expert(s):
Amotz Shemi (Chief Executive Officer, Silenseed)
To request sample pages, please visit this https://www.rootsanalysis.com/reports/278/request-sample.html
KeyQuestions Answered
§ Whoare the leading industry players in this market?
§ Whatare the clinical conditions for which RNAi therapeutics are being developed?
§ Whoare the key investors in the RNAi therapeutics market?
§ Whatkind of commercialization strategies are being adopted by RNAi therapeuticsdevelopers?
§ Whatare the different promotional and reimbursement strategies used for RNAitherapeutics?
§ Whatare the prevalent R&D trends related to RNAi therapeutics?
§ Whatare the various delivery / technology platforms that are being used for thedevelopment of RNAi therapeutics?
§ Whatkind of partnership models are used by stakeholders in this industry?
§ Whoare the key service providers in this field of therapeutics?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
Youmay also be interested in the following titles:
1. Gene Therapy Market (3rdEdition), 2019-2030
2. Global T-Cell (CAR-T,TCR and TIL) Therapy Market (4th Edition), 2019-2030
3. Biopharma ContractManufacturing Market (3rd Edition), 2019-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
